Evidence map›Paper›PMID 33619480›Full record

ArticlebioRxiv : the preprint server for biology2021

A Combination Adjuvant for the Induction of Potent Antiviral Immune Responses for a Recombinant SARS-CoV-2 Protein Vaccine.

Sonia Jangra, Jeffrey J Landers, Raveen Rathnasinghe, Jessica J O'Konek, Katarzyna W Janczak, Marilia Cascalho, Andrew A Kennedy, Andrew W Tai, James R Baker, Michael Schotsaert and 1 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Sonia Jangra
Jeffrey J Landers
Raveen Rathnasinghe
Jessica J O'Konek
Katarzyna W Janczak
Marilia Cascalho
Andrew A Kennedy
Andrew W Tai
James R Baker
Michael Schotsaert
Pamela T WongORCID 0000-0002-4387-4723
University of Michigan · USIcahn School of Medicine at Mount Sinai · US

Funding

Donor-specific B cells in Transplantation.R01AI151588 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CASCALHO, MARILIA ISABEL, PLATT, JEFFREY L · 2020 to 2025
$2.7M
NIAID NIH HHS R01 AI151588
6 · The paper itself

Abstract

Several SARS-CoV-2 vaccines have received EUAs, but many issues remain unresolved, including duration of conferred immunity and breadth of cross-protection. Adjuvants that enhance and shape adaptive immune responses that confer broad protection against SARS-CoV-2 variants will be pivotal for long-term protection. We developed an intranasal, rationally designed adjuvant integrating a nanoemulsion (NE) that activates TLRs and NLRP3 with an RNA agonist of RIG-I (IVT DI). The combination adjuvant with spike protein antigen elicited robust responses to SARS-CoV-2 in mice, with markedly enhanced T

Identifiers

PMID33619480
PMCPMC7899444
OpenAlexW3131920741

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.